TY - JOUR
T1 - First-line treatment and overall survival in EGFR mutation-positive advanced non-small cell lung cancer
T2 - a national cohort study
AU - Huang, L. Y.
AU - Chang, H. P.
AU - Chang, R. Y.
AU - Tai, H. Y.
AU - Huang, Y. W.
AU - Lee, P. C.
N1 - Publisher Copyright:
© 2022 Verduci Editore s.r.l. All rights reserved.
PY - 2022
Y1 - 2022
N2 - OBJECTIVE: Non-squamous non-small cell lung cancer (NSCLC) is the first leading cause of cancer-related deaths in Taiwan. This study aimed at evaluating the effectiveness of first-line targeted therapy for advanced epidermal growth factor receptor (EGFR) mutation-positive non-squamous NSCLC in Taiwan. PATIENTS AND METHODS: This was a real-world, retrospective, observational study of patients diagnosed with advanced non-squamous NSCLC (N=63,248). Between 2011 and 2019, 19,458 patients received targeted therapy and 22,994 patients received chemotherapy alone; between 2002 and 2010, 20,796 patients received chemotherapy alone. Overall survival (OS) was determined. RESULTS: The median OS for patients treated with first-line targeted therapy (22.9 months) was longer than that of patients receiving chemotherapy alone (11.7 months). HR: 0.521, log-rank test, p<0.001. CONCLUSIONS: These data represent the potential survival outcomes of Taiwanese patients with advanced EGFR mutation-positive non-squamous NSCLC in clinical practice.
AB - OBJECTIVE: Non-squamous non-small cell lung cancer (NSCLC) is the first leading cause of cancer-related deaths in Taiwan. This study aimed at evaluating the effectiveness of first-line targeted therapy for advanced epidermal growth factor receptor (EGFR) mutation-positive non-squamous NSCLC in Taiwan. PATIENTS AND METHODS: This was a real-world, retrospective, observational study of patients diagnosed with advanced non-squamous NSCLC (N=63,248). Between 2011 and 2019, 19,458 patients received targeted therapy and 22,994 patients received chemotherapy alone; between 2002 and 2010, 20,796 patients received chemotherapy alone. Overall survival (OS) was determined. RESULTS: The median OS for patients treated with first-line targeted therapy (22.9 months) was longer than that of patients receiving chemotherapy alone (11.7 months). HR: 0.521, log-rank test, p<0.001. CONCLUSIONS: These data represent the potential survival outcomes of Taiwanese patients with advanced EGFR mutation-positive non-squamous NSCLC in clinical practice.
KW - Adenocarcinoma
KW - Epidermal growth factor receptor
KW - Non-Squamous non-small cell lung cancer
KW - Overall survival
KW - Tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=85141003457&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141003457&partnerID=8YFLogxK
U2 - 10.26355/eurrev_202210_30039
DO - 10.26355/eurrev_202210_30039
M3 - Article
C2 - 36314347
AN - SCOPUS:85141003457
SN - 1128-3602
VL - 26
SP - 7632
EP - 7640
JO - European Review for Medical and Pharmacological Sciences
JF - European Review for Medical and Pharmacological Sciences
IS - 20
ER -
